What does pemvidutide target?

The GLP-1 and glucagon receptors — the same pair as survodutide and mazdutide.

Why is it studied in liver disease?

Glucagon receptor agonism mobilises hepatic fat, so the mechanism acts directly on the tissue where steatotic liver disease begins.

GLP-1 & Incretin Science

A GLP-1/Glucagon Dual Aimed at the Liver

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Pemvidutide is a dual agonist of the GLP-1 and glucagon receptors. Browne and colleagues published a randomised controlled trial of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease in JHEP Reports in November 2025.

Key facts

Class: GLP-1 / glucagon dual agonist
Trial duration: 24 weeks
Condition studied: MASLD
Published: JHEP Rep, November 2025 (PMID 41113119)
Design: Randomised, controlled
Same receptor pair as: Survodutide, mazdutide
Authorisation: None

Why glucagon agonism points at the liver

Glucagon receptor activation increases energy expenditure and mobilises hepatic fat. That second effect is what makes a GLP-1/glucagon dual agonist a liver compound as much as a weight compound — it acts directly on the tissue where steatotic liver disease begins, rather than only reducing the adiposity upstream of it.

Why the liver indication is pursued so hard in this class

Because the mechanism suits it and because the need is substantial. Survodutide and mazdutide share the receptor pair and have both been studied with hepatic endpoints in view. A compound whose glucagon arm mobilises liver fat is being aimed at the organ that arm acts on, which is a more direct rationale than most indication expansion in this field.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

MASLD and MASH are not the same endpoint

Metabolic dysfunction-associated steatotic liver disease covers fat accumulation; steatohepatitis adds inflammation and cell injury. Trials in the two report different things, and the published trial here names MASLD. Reading a steatosis result as though it were a steatohepatitis result overstates it, and the terms are close enough to be conflated easily.

Why 24 weeks fits a liver endpoint better than a weight one

Hepatic fat responds relatively quickly and can be measured by imaging rather than requiring biopsy. Twenty-four weeks is short for a weight-reduction trial and reasonable for a change in liver fat content, which is one reason liver programmes can read out sooner than the histological endpoints described elsewhere on this site.

The glucagon trade-off

Glucagon raises blood glucose, which is why glucagon receptor agonism only works alongside sufficient GLP-1 activity to offset it. The balance between the two arms is the central design parameter, and it is fixed at the molecule level — the same constraint retatrutide faces with its third receptor.

Regulatory position

Pemvidutide holds no marketing authorisation anywhere and is investigational. Nothing supplied on this site is related to it or is an alternative to any treatment for liver disease.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What does pemvidutide target?: The GLP-1 and glucagon receptors — the same pair as survodutide and mazdutide.
Why is it studied in liver disease?: Glucagon receptor agonism mobilises hepatic fat, so the mechanism acts directly on the tissue where steatotic liver disease begins.
Is MASLD the same as MASH?: No. MASLD covers fat accumulation; steatohepatitis adds inflammation and cell injury. The published trial names MASLD.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum